sTMS for Substance Use-disordered Veterans
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
All non-life-saving human research studies suspended by sponsor in response to COVID19 social distancing policies
The goal of this proposal is to evaluate preliminary participant response to a pilot, controlled, feasibility study to evaluate changes in craving, substance use, and quality of life after 6 weeks of a low-risk non-invasive brain stimulation technique, called Synchronized Transcranial Magnetic Stimulation (sTMS), compared to sham, in Veterans with a substance use disorder (SUD). An important focus of this application will be evaluating the acceptability, tolerability, and safety of sTMS in this population. To the investigators knowledge, sTMS has never been used for SUDs, and holds considerable promise as a future treatment option for these prevalent disorders. However initial work in the acceptability, tolerability, and safety of this approach must be conducted first. This project is the first step towards the investigators long-term goal, which is to combine non-invasive brain stimulation with individualized psychotherapy or pharmacotherapy to reduce SUD problems and improve quality of life for Veterans.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: John E McGeary, PhD
- Phone Number: 3393 (401) 273-7100
- Email: John.McGeary@va.gov
Study Contact Backup
- Name: Noah S Philip, MD
- Phone Number: 6200 (401) 273-7100
- Email: noah.philip@va.gov
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02908-4734
- Providence VA Medical Center, Providence, RI
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Eligible male and female Veterans
- between ages 18-70,
- Veterans who currently meet criteria for SUD, and, if applicable, have stable treatment regimen (i.e., medications and/or therapy) for at least 6 weeks prior to study procedures
- ongoing medications and psychotherapy will be allowed to continue unchanged during the study
- for safety, participants must also meet established criteria for MRI exposure, which is implemented as a conservative measure given the novel application of sTMS in this population
Exclusion Criteria:
- pregnancy/lactation,
- history of moderate or severe traumatic brain injury,
current or prior neurologic disorder or lifetime history of
- seizure disorder
- CNS tumors
- stroke
- cerebral aneurysm,
unstable medical condition,
- active suicidality as assessed with the Columbia-Suicide Severity Rating Scale
- primary psychotic disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: active
active sTMS
|
sTMS will be delivered following NeoSync guidelines using the device user manual |
|
Sham Comparator: sham
sham sTMS
|
sham sTMS will be delivered following NeoSync guidelines using the device user manual
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF)
Time Frame: 6 weeks
|
Quality of Life Enjoyment and Satisfaction Questionnaire The Q-LES-Q-SF evaluates general activities that are assessed in the longer form of the Q- LES-Q. Each item uses a 5-point scale ranging from 1 (very poor) to 5 (very good). A total score is derived from 14 items with a maximum score of 70 and with higher scores indicating greater life satisfaction and enjoyment. |
6 weeks
|
|
substance specific craving
Time Frame: 6 weeks
|
self reported reactivity to associated cues with 8 items ranked 1-7--higher scores indicating greater craving/urges
|
6 weeks
|
|
Social and Occupational Functioning Assessment Scale (SOFAS)
Time Frame: 6 weeks
|
The SOFAS is a global rating of current functioning ranging from 0 to 100, with lower scores representing lower functioning.
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: John E McGeary, PhD, Providence VA Medical Center, Providence, RI
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D3338-P
- RX003338 (Other Grant/Funding Number: VA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Addiction
-
NCT04599270RecruitingAddiction, Substance | Addiction, Alcohol
-
NCT01586689CompletedDrug/Substance Abuse/Addiction | Alcohol Abuse/Addiction
-
NCT05042180RecruitingAddiction, Alcohol | Alcohol Dependence, in Remission
-
NCT03232112CompletedAddiction, Alcohol | Alcohol Dependence, in Remission
-
NCT07216872RecruitingAlcohol Dependence | Alcoholism | Alcohol Use Disorder | Alcohol Abuse | Alcohol Addiction | Alcohol Abuse/Dependence
-
NCT05434416RecruitingAddiction | Addiction, Substance | Addiction, Alcohol
-
NCT04990765RecruitingAddiction, Alcohol | Alcohol Dependence, in Remission
-
NCT07369245Not yet recruiting
-
NCT07131124Not yet recruitingAlcohol Dependence | Alcohol Use Disorders | Addiction | Addiction Disorders
Clinical Trials on sTMS
-
NCT02708472WithdrawnGeneralized Anxiety Disorder (GAD)
-
NCT02981381CompletedDepression | PTSD
-
NCT07063446RecruitingHemiplegia | Perinatal Brain Injury
-
NCT03288714CompletedDepressive Disorder | Depression | Depressive Disorder, Major | Major Depressive Disorder | Depressive Episode